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Immunogenicity and Safety of Trivalent Inactivated Influenza 
Vaccine: A Randomized, Double-Blind, Multi-Center, Phase 3 
Clinical Trial in a Vaccine-Limited Country 
Influenza vaccines are the primary method for controlling influenza and its complications. 
This study was conducted as a phase 3, randomized, double-blind, controlled, multi-
center trial at seven university hospitals to evaluate the immunogenicity and safety of an 
inactivated, split, trivalent influenza vaccine (GC501, Green Cross Corporation, Yongin, 
Korea), which was newly manufactured in Korea in 2008. Between September 21 and 26, 
a total of 329 healthy subjects were recruited for the immunogenicity analysis, while 976 
subjects were enrolled for the safety analysis. The GC501 vaccine met both FDA and EMEA 
criteria with ≥ 80% of subjects achieving post-vaccination titers ≥ 40 for all three 
subtypes, even in the elderly. The vaccine was well tolerated with only mild systemic and 
local adverse events. In summary, GC501 showed excellent immunogenicity and a good 
safety profile in both young adults and the elderly. The licensure of GC501 might be an 
important basis in preparation for the future influenza pandemic.
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INTRODUCTION
Influenza and its complications have a large social impact in-
cluding increased demands on the healthcare system and pa-
tient disability and mortality. Annually, the World Health Orga-
nization (WHO) estimates that there are 3-5 million cases of se-
vere influenza illness, resulting in 250,000-500,000 deaths in in-
dustrialized countries (1). In the Republic of Korea (ROK), the 
Korean Influenza Surveillance Scheme (KISS) has been opera-
tional in public health centers and private clinics since the year 
2000, and about 20% of the general population is presumed to 
get the flu every year (2, 3). In addition to its social impact, in-
fluenza also has a significant economic impact, including lost 
or reduced productivity in the work place, work and school ab-
senteeism, and increased healthcare costs.
  Influenza vaccines are the primary method for controlling 
influenza and its complications. In the ROK, the influenza vac-
cine coverage rate in the general population is 34.3%, while the 
coverage rate in the priority group is 61.3%; higher than the rates 
of other countries (4). Despite the high vaccination rate in the 
ROK, all influenza vaccines prior to 2008 were imported from 
global vaccine manufacturers. In 2008, the Green Cross Corpo-
ration of the ROK started to produce an influenza vaccine. Here-
in, a multi-center, randomized trial of inactivated trivalent in-
fluenza vaccine was conducted for the purposes of licensure.
MATERIALS AND METHODS
Study design
This study was conducted as a randomized, double-blind, con-Song JY, et al.  •  Trial of Inactivated Trivalent Influenza Vaccine in a Vaccine-Limited Country
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trolled, multi-center, phase 3 trial at seven university hospitals 
in the ROK to evaluate the immunogenicity and safety of an in-
activated, split, trivalent influenza vaccine (GC501, Green Cross 
Corporation) newly manufactured in Korea in 2008 (Clinical trial 
number-KCT0000034). Immunogenicity of the GC501 was com-
pared to that of the control vaccine (Fluarix
®, GlaxoSmithKline 
Biologicals, Rixensart, Belgium). Subjects (healthy adults aged 
≥ 18 yr) were excluded for the following reasons: allergy to eggs, 
history of Guillain-Barre syndrome, immunodeficiency or receipt 
of immunosuppressive therapy, active neoplastic diseases, and 
previous influenza vaccination within six months prior to the 
study. Subjects who met the entry criteria for the study were strat-
ified into two age groups (18-59 and ≥ 60 yr) and randomized to 
receive either the study vaccine or the control vaccine.
  After a baseline blood sample was collected, the vaccine was 
administered as a single intramuscular injection into the deltoid 
muscle, and subjects were observed for 30 min. At day 21 after 
vaccination, a second blood sample was obtained. 
Vaccines 
The study vaccine (GC501) was a trivalent, inactivated split vac-
cine loaded into pre-filled syringes containing 15 µg of hemag-
glutinin and was produced in embryonated chicken eggs by the 
Green Cross Corporation (Yongin, ROK) according to the guide-
lines of the WHO. The control vaccine was a 0.5 mL commercial 
trivalent, inactivated split vaccine (Fluarix
®) in pre-filled syringes 
containing 15 µg of hemagglutinin. The vaccines were each com-
posed of the following influenza strains: A/Brisbane/59/2007 
IVR-148 (H1N1), A/Uruguay/716/2007 NYMC X-175C (H3N2), 
and B/Brisbane/3/2007.
 
Immunogenicity assessment
Serum samples were assessed for hemagglutination-inhibition 
(HI) antibodies to each hemagglutinin of the H1N1, H3N2 and 
B strains contained in the vaccine using a standard assay with 
use of chicken erythrocytes at the Korea University Guro Hospi-
tal (5). HI antibody titers that were below the detection limit (i.e., 
< 1:10) were assigned a value of 1:5, and all other titers over 
1:5,120 were assigned a value of 1:5,120.
  The three co-primary immunogenicity end points after vac-
cination were the proportion of subjects with antibody titers of 
1:40 or more on HI assays (seroprotection rate), the proportion 
of subjects with either seroconversion or a four-fold or more in-
crease in antibody titer (seroconversion rate), and geometric 
mean titer ratio (GMTR) (i.e., the ratio of the geometric mean 
titer after vaccination to the geometric mean titer before vacci-
nation) (6). Serologic response, as measured by HI antibody ti-
ters, was assessed using the criteria set by both the United States 
Food and Drug Administration (FDA) and the Committee for 
Proprietary Medicinal Products (CPMP) of the European Agen-
cy for the Evaluation of Medicinal Products (EMEA). According 
to the FDA criteria, the lower bound of the two-sided 95% con-
fidence interval (CI) of seroprotection should meet or exceed 
70% in adults aged < 65 yr (60% in adults ≥ 65 yr), and the lower 
bound of the two-sided 95% CI of seroconversion should meet 
or exceed 40% in adults aged < 65 yr (30% in adults ≥ 65 yr) (7). 
In order to confirm protective immunogenicity based on the 
EMEA criteria, one of the following criteria must be met: sero-
protection rates > 70% for subjects aged 18-60 yr and > 60% for 
subjects over 60 yr, seroconversion rates > 40% for subjects aged 
18-60 yr and > 30% for subjects over 60 yr, or GMT ratios > 2.5 
for subjects aged 18-60 yr and > 2.0 for subjects over 60 yr (6).
 
Safety assessment 
At first visit, enrolled subjects were given a digital thermometer 
and a diary card containing of a list of solicited adverse events 
and their grades. On the immunization day (day 0), subjects were 
observed at the study site for a period of 30 min after vaccination 
to detect any immediate adverse reactions. For the next 7 days, 
subjects were educated to record the severity of solicited local 
adverse events and solicited systemic adverse events, axillary 
temperature and concomitant medications in the diary card. 
Subjects used a standard scale to grade adverse events (8).
  Solicited local adverse events were pain, tenderness, redness 
and swelling, and solicited systemic adverse events were fever, 
headache, malaise, shivering, fatigue, sweating, myalgia and 
arthralgia. We collected unsolicited reports during the study. 
Serious adverse events were reported within 24 hr. Any adverse 
events were possibly considered to be related to the vaccine for 
up to six months after vaccination.
Statistical analysis 
The sample size was chosen to meet the immunogenicity end-
points based on the data of the Fluarix
® trial (9). All statistics 
were generated using SPSS 11.5. The Student t-test (Mann Whit-
ney U-test for less than 30 samples) was used to compare HI ti-
ters between the two groups. HI titers obtained before and after 
vaccination were compared using the Wilcoxon test (two-tailed), 
and categorical variables were analyzed using the chi-square 
test. Results were considered statistically significant if the P val-
ue was less than 0.05.
 
Ethics statement
The study was conducted in accordance with the Declaration of 
Helsinki and the standards of Good Clinical Practice by the In-
ternational Conference on Harmonization. The protocol and 
consent forms were approved by the institutional review board 
of each participating study site. Informed written consent was 
obtained from all participants following a detailed explanation 
of schedules and study contents.
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RESULTS
Study subjects
Between September 21 and 26, 2008, a total of 329 healthy sub-
jects were recruited for the analysis of immunogenicity, while 
976 subjects were enrolled for the safety analysis (Fig. 1). Three 
hundred and nineteen subjects were randomized to receive ei-
ther the study vaccine (GC501, 130 subjects aged 18-59 yr and 
132 subjects aged ≥ 60 yr) or the control vaccine (Fluarix
®, 32 
subjects aged 18-59 yr and 35 subjects aged ≥ 60 yr). The demo-
graphic and baseline characteristics of the two vaccine groups 
were well matched, as shown in Table 1. All 976 subjects in the 
safety analysis received the study vaccine.
Immunogenicity
Pre-vaccination GMTs were similar between the GC501 and con-
trol vaccine groups in both subjects aged 18-59 yr and in sub-
jects aged ≥ 60 yr (Table 2). Table 2 presents the immunogenicity 
data on the seroprotection, seroconversion and GMTR of 329 
subjects by intent-to-treat (ITT) analysis. For each strain of the 
three subtypes, the seroprotection rates, seroconversion rates 
and GMTRs were comparable between the GC501 and control 
vaccine groups, irrespective of age (P > 0.05). The GC501 vaccine 
met both the FDA and EMEA criteria. In terms of the GC501 vac-
cine, seroprotection rates were 88.5% for A/H1N1, 80.0% for A/
H3N2 and 94.6% for B in subjects aged 18-59 yr and were 81.8% 
for A/H1N1, 81.1% for A/H3N2 and 82.6% for B in subjects aged  Fig. 1. Flowchart of subjects through the study.
Blood samples 
at day 0 and day 21
· Solicited adverse
event
-systemic
-local
· Unsolicited adverse 
event
Immunogenicity analysis
329 subjects randomized
Safety
analysis
976 subjects included
-803 aged 18-59 yr
-173 aged ≥ 60 yr
Study vaccine
(GC501): 262 subjects
-130 aged 18-59 yr
-132 aged ≥ 60 yr
Control vaccine
(Fluarix
®): 67 subjects
-32 aged 18-59 yr
-35 aged ≥ 60 yr
Table 1. Demographic characteristics of the study subjects 
Subjects aged 18-59 yr Subjects aged ≥ 60 yr
GC501 (n = 130) Control (n = 32) P value GC501 (n = 132) Control (n = 35) P value
Sex (male), No. (%) 52 (40.0%) 11 (34.4%) 0.559 50 (37.9%) 13 (37.1%) 0.936
Age, mean ± SD (yr) 34.3 ± 9.8   36.8 ± 10.7 0.200 65.2 ± 4.7 66.3 ± 5.3 0.267
BMI, mean ± SD 22.8 ± 3.3 23.8 ± 3.5 0.917 24.7 ± 2.9 24.4 ± 2.6 0.236
Smoking, No. (%) 29 (22.3%) 2 (6.3%) 0.018 8 (6.1%)   4 (11.4%) 0.528
Alcohol, No. (%) 56 (43.1%) 12 (37.5%) 0.751 29 (22.0%)   4 (11.4%) 0.244
BMI, body mass index.
Table 2. Immune responses after immunization with trivalent inactivated influenza vaccines, as measured using a hemagglutination-inhibition (HI) assay: GC501 versus control 
vaccine (Fluarix
®)
Immunogenicity
Subjects aged 18-59 yr Subjects aged ≥ 60 yr
  GC501   Control P value   GC501   Control P value
H1N1
   Seroprotection
   Seroconversion
   GMTR
   GMT (day 0)
   GMT (day 21)
 
  88.5 (81.4-93.2)
  66.2 (57.3-74.1)
10.1 (7.5-13.5)
  15.4 (12.4-18.9)
    155.0 (120.8-197.5)
 
  87.5 (70.1-95.9)
  71.9 (53.0-85.6)
13.5 (7.0-26.0)
  18.0 (10.6-30.5)
    241.5 (139.6-420.3)
 
0.88
0.54
0.41
0.54
0.13
 
  81.8 (74.0-87.8)
  53.0 (44.2-61.7)
5.1 (4.1-6.4)
  16.1 (13.1-19.8)
    81.9 (66.8-101.3)
 
  74.3 (56.4-86.9)
  37.1 (22.0-55.1)
3.5 (2.4-5.3)
  17.4 (11.7-26.1)
  61.2 (41.1-90.4)
 
0.32
0.10
0.15
0.74
0.21
H3N2
   Seroprotection
   Seroconversion
   GMTR
   GMT (day 0)
   GMT (day 21)
 
  80.0 (71.9-86.3)
  73.1 (64.5-80.3)
11.1 (8.3-15.0)
8.1 (6.9-9.5)
    90.4 (67.1-120.8)
 
  75.0 (56.3-87.9)
  75.0 (56.3-87.9)
13.2 (8.1-21.5)
  7.7 (5.8-10.2)
  101.5 (60.8-169.5)
 
0.53
0.83
0.61
0.77
0.73
 
  81.1 (73.1-87.2)
  66.7 (57.9-74.5)
  8.8 (6.8-11.3)
  13.0 (10.6-16.2)
  113.7 (88.5-145.1)
 
  80.0 (62.5-90.9)
  68.6 (50.6-82.6)
  8.2 (5.2-13.2)
12.2 (8.8-17.0)
  100.5 (61.5-164.1)
 
0.89
0.83
0.83
0.78
0.66
B
   Seroprotection
   Seroconversion
   GMTR
   GMT (day 0)
   GMT (day 21)
 
  94.6 (88.8-97.6)
  53.1 (44.2-61.8)
4.0 (3.2-5.2)
  34.7 (27.1-44.7)
    140.4 (116.5-167.7)
 
100 (NA)
  68.8 (49.9-83.3)
  6.7 (4.1-11.2)
  24.8 (15.8-38.9)
    167.1 (123.8-226.2)
 
0.18
0.11
0.07
0.23
0.39
 
  82.6 (74.8-88.4)
  50.0 (41.2-58.8)
4.8 (3.9-6.0)
  18.2 (14.7-22.5)
    87.5 (70.6-108.1)
 
  85.7 (69.0-94.6)
  42.9 (26.8-60.5)
4.0 (2.7-6.0)
  24.4 (15.9-37.1)
    97.5 (67.5-140.9)
 
0.66
0.45
0.44
0.22
0.64
Geometric mean ratios are the ratios of the antibody levels at day 21 and at day 0. Seroconversion was defined as a pre-vaccination antibody titer of 1:10 or less and a post-
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≥ 60 yr. Likewise, seroconversion rates were 66.2% for A/H1N1, 
73.1% for A/H3N2 and 53.1% for B in subjects aged 18-59 yr and 
were 53.0% for A/H1N1, 66.7% for A/H3N2 and 50.0% for B in 
subjects aged ≥ 60 yr. GMTRs ranged between 4.0 and 16.1 and 
were lower with regard to subtype B compared to those of A/
H1N1 and A/H3N2.
 
Safety
Solicited local and systemic adverse events reported within sev-
en days of vaccination are shown in Table 3. Following the vac-
cination, 595 (61.0%) of the 976 subjects reported solicited local 
adverse events, while 388 subjects (39.8%) reported solicited 
systemic adverse events. Overall, solicited adverse events were 
less common in the elderly group aged ≥ 60 yr (82 among 173 
subjects, 47.4%) compared to those of the subjects aged 18-59 yr 
(587 among 803 subjects, 73.1%). The most common local ad-
verse events were pain (451, 46.2%) and tenderness (510, 52.3%), 
while the most frequent systemic event was fatigue (232, 23.8%), 
followed by headache (189, 19.4%) and myalgia (179, 18.3%). 
Most subjects reported systemic adverse events as grade 1 (no-
ticeable but did not interfere with daily activity) that resolved 
within three days. High-grade systemic adverse events (≥ grade 
2) were observed in 6.9% of subjects: fatigue (22, 2.3%), head-
ache (19, 1.9%), myalgia (16, 1.6%), malaise (11, 1.1%) and shiv-
ering (11, 1.1%).
  During the 21 days after vaccination, unsolicited adverse 
events were reported by 86 (8.8%) of the 976 subjects. Of these, 
respiratory system disorder (31, 3.2%) was the most common, 
and 32 (3.3%) of the events were considered to be related to vac-
cination. On the other hand, two severe adverse events of atel-
ectasis and convulsion were reported. Atelectasis was not con-
sidered to be related to vaccination, while the episode of con-
vulsion was possibly related. All subjects with unsolicited ad-
verse events recovered without sequelae, and no death was re-
ported.
DISCUSSION
This study showed that the immunogenicity of the new influen-
za vaccine (GC501) is largely comparable with that of the com-
mercial trivalent, inactivated split vaccine (Fluarix
®, GlaxoSmith-
Kline Biologicals, Rixensart, Belgium), which was well tolerated.
  Up until the early 21st century, about 85% of the world’s sup-
ply of influenza vaccine had been produced by nine vaccine 
companies located in nine different countries: France, Germa-
ny, Italy, the Netherlands, Switzerland, the United Kingdom, the 
United States, Canada, and Australia (10). In the situation of large 
influenza epidemic, any country would be confronted with vac-
cine shortage. Concerning vaccine shortage, some Asian coun-
tries had tried to have their own manufacturing system. Japan 
already has four national influenza vaccine manufacturers, and 
China recently achieved licensure of an influenza vaccine. The 
GC501 vaccine in this study is the first Korean influenza vaccine 
which is expected to contribute to lowering the risk of vaccine 
shortages in the many vaccine-limited countries.
  For the licensure of a new influenza vaccine, the FDA and 
EMEA provide definite criteria that must be achieved (6, 7). In 
the present study, GC501 met the FDA requirements with con-
sistent rates of seroprotection (lower bound of the two-sided 
95% CI ≥ 70%) and seroconversion (lower bound of the two-sid-
ed 95% CI ≥ 40%) for all three subtypes, irrespective of age. As 
for the EMEA criteria, GC501 exceeded the requirements with 
≥ 80% of subjects achieving post-vaccination titers ≥ 40 for all 
three subtypes, even in the elderly.
Table 3. Solicited local and systemic adverse events within seven days after GC501 vaccination 
Adverse event (%)
18-59 yr (n = 803) ≥ 60 yr (n = 173)
   All grades ≥ Grade 2     All grades  ≥ Grade 2
Solicited local event
   Pain
   Tenderness
   Redness
   Swelling
 
    50.6 (47.1-54.1)
    57.8 (54.3-61.2)
  7.6 (5.9-9.7)
  2.9 (1.9-4.3)
 
0.4 (0.1-1.2)
1.0 (0.5-2.0)
1.5 (0.8-2.7)
0.6 (0.2-1.5)
 
     26.0 (19.8-33.3)
     26.6 (20.3-33.9)
     9.3 (5.6-14.8)
   2.9 (1.1-7.0)
 
-
  1.2 (0.2-4.6)
  1.7 (0.5-5.4)
-
Solicited systemic event
   Fever
   Headache
   Shivering
   Malaise
   Fatigue
   Sweating
   Myalgia
   Arthralgia
 
 0.1 (0-0.8)-
    20.7 (18.0-23.7)
  10.0 (8.0-12.3)
    12.3 (10.2-14.9)
    25.9 (22.9-29.1)
  6.2 (4.7-8.2)
    20.2 (17.5-23.2)
  4.1 (2.9-5.8)
 
-
2.4 (1.5-3.7)
1.3 (0.6-2.4)
1.3 (0.6-2.4)
2.2 (1.4-3.6)
1.0 (0.5-2.0)
1.9 (1.1-3.1)
0.4 (0.1-1.2)
 
0.6 (0-3.7)
   13.3 (8.8-19.5)
     7.5 (4.2-12.8)
     5.8 (3.0-10.7)
   13.9 (9.3-20.1)
     6.9 (3.8-12.1)
     9.8 (6.0-15.5)
   5.2 (2.6-9.8)
 
0.6 (0-3.7)
-
0.6 (0-3.7)
0.6 (0-3.7)
  2.3 (0.7-6.2)
-
0.6 (0-3.7)
0.6 (0-3.7)
*Data are presented as proportion (95% confidence interval) of participants who reported having a solicited local or systemic adverse event. Pain was grade 0 (absent), grade 1 
(does not interfere with activity), grade 2 (repeated use of non-narcotic pain reliever > 24 hr or interferes with activity), grade 3 (any use of narcotic pain reliever or prevents 
daily activity), or grade 4 (emergency room visit or hospitalization). Tenderness was grade 0 (absent), grade 1 (mild discomfort to touch), grade 2 (discomfort with movement), 
grade 3 (significant discomfort at rest), or grade 4 (emergency room visit or hospitalization). Other adverse events were grade 1 (does not interfere with activity), grade 2 (interferes 
with activity), grade 3 (prevents daily activity), or grade 4 (emergency room visit or hospitalization).Song JY, et al.  •  Trial of Inactivated Trivalent Influenza Vaccine in a Vaccine-Limited Country
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  In general, local reactions after inactivated influenza vaccina-
tion are known to be relatively frequent (10%-65%) (11). Consis-
tent with previous reports, GC501 showed mild local reactions 
in 61.0% of subjects. Though the frequency of systemic adverse 
reactions to GC501 (39.8%) was higher than those in previous 
reports (15% in average) (10), most adverse reactions were grade 
1 and were resolved spontaneously within a few days. One epi-
sode of convulsion was reported by a vaccine recipient (0.1%) 
and was considered to be possibly vaccine-related. However, 
the subject recovered without sequelae, and the episode was 
not recurrent.
  In summary, GC501 showed excellent immunogenicity and 
a good safety profile in both young adults and the elderly. The 
licensure of GC501 might be an important basis in preparation 
for the future influenza pandemic.
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